Cellexus

Executive Summary

Cellexus is a UK-based biotechnology company specializing in single-use airlift bioreactor systems. Founded in 2015 and headquartered in Cambridge, the company has developed the CellMaker platform, a flexible solution designed to improve and simplify cell culture and fermentation processes for microbial, bacteriophage, and mammalian cell applications. By focusing on single-use technology, Cellexus addresses key challenges in bioprocessing, such as contamination risk and time-consuming cleaning protocols, enabling faster R&D and more efficient production for clients in cell therapy and biologics. The company positions itself as a provider of bespoke, user-friendly bioreactor systems that accelerate development timelines. While still private with no disclosed funding rounds, Cellexus's technology holds potential for niche applications in phage therapy and cell therapy where traditional stirred-tank reactors may be suboptimal. The single-use airlift design offers advantages in scalability, oxygen transfer, and reduced shear stress. Going forward, Cellexus may benefit from increased adoption of single-use technologies in biopharma and growing interest in bacteriophage therapeutics. Key upcoming catalysts include new customer partnerships, product line expansions, and potential funding rounds to scale commercialization.

Upcoming Catalysts (preview)

• TBDStrategic partnership with a major biopharma company for CellMaker deployment40% success
• TBDLaunch of an enhanced CellMaker variant targeting high-density mammalian cell culture50% success
• TBDSeries A funding round to scale manufacturing and sales60% success